BIOMAT Database Logo BIOMAT Database Logo

Combined administration of misoprostol in the first and second trimester missed abortion cases. 2006

T Kutlu, and S Tuğrul, and T Aran, and H Uslu, and S Eren, and O Oral
Zeynep Kamil Women and Children's Education and Research Hospital, Istanbul, Turkey.

OBJECTIVE We aimed to investigate the effectiveness and adverse effects of combined (vaginal + oral) administration of misoprostol in missed abortion cases. METHODS 48 missed abortion cases between 8 and 20 weeks of gestation were enrolled in this study. Misoprostol-induced medical abortion was planned; the first dose (200 microg) was administered intravaginally and subsequent doses (200 microg each) orally every following hour. A maximum of six doses (1200 microg) were used. Revision curettage was performed on all subjects who aborted. RESULTS The mean time interval from the first dose of misoprostol until the abortion was 6.27 +/- 3.02 hours. The success rate was 95% for the whole group. We observed misoprostol-related trembling in one patient and fever in two patients. CONCLUSIONS We believe that our low-dose combined misoprostol protocol is a safe, effective and well-tolerated method with minimal adverse effects for the termination of both first and second trimester pregnancy losses.

UI MeSH Term Description Entries
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011261 Pregnancy Trimester, First The beginning third of a human PREGNANCY, from the first day of the last normal menstrual period (MENSTRUATION) through the completion of 14 weeks (98 days) of gestation. Early Placental Phase,Pregnancy, First Trimester,Trimester, First,Early Placental Phases,First Pregnancy Trimester,First Pregnancy Trimesters,First Trimester,First Trimester Pregnancies,First Trimester Pregnancy,First Trimesters,Phase, Early Placental,Phases, Early Placental,Placental Phase, Early,Placental Phases, Early,Pregnancies, First Trimester,Pregnancy Trimesters, First,Trimesters, First
D011262 Pregnancy Trimester, Second The middle third of a human PREGNANCY, from the beginning of the 15th through the 28th completed week (99 to 196 days) of gestation. Midtrimester,Pregnancy, Second Trimester,Trimester, Second,Midtrimesters,Pregnancies, Second Trimester,Pregnancy Trimesters, Second,Second Pregnancy Trimester,Second Pregnancy Trimesters,Second Trimester,Second Trimester Pregnancies,Second Trimester Pregnancy,Second Trimesters,Trimesters, Second
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000020 Abortifacient Agents, Nonsteroidal Non-steroidal chemical compounds with abortifacient activity. Abortifacient Agents, Non-Steroidal,Abortifacient Agents, Non Steroidal,Agents, Non-Steroidal Abortifacient,Agents, Nonsteroidal Abortifacient,Non-Steroidal Abortifacient Agents,Nonsteroidal Abortifacient Agents
D000030 Abortion, Missed The retention in the UTERUS of a dead FETUS two months or more after its DEATH. Abortions, Missed,Missed Abortion,Missed Abortions
D000282 Administration, Intravaginal The insertion of drugs into the vagina to treat local infections, neoplasms, or to induce labor. The dosage forms may include medicated pessaries, irrigation fluids, and suppositories. Administration, Vaginal,Drug Administration, Vaginal,Instillation, Vaginal,Intravaginal Administration,Vaginal Drug Administration,Vaginal Administration,Administration, Vaginal Drug,Administrations, Intravaginal,Administrations, Vaginal,Administrations, Vaginal Drug,Drug Administrations, Vaginal,Instillations, Vaginal,Intravaginal Administrations,Vaginal Administrations,Vaginal Drug Administrations,Vaginal Instillation,Vaginal Instillations
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D016595 Misoprostol A synthetic analog of natural prostaglandin E1. It produces a dose-related inhibition of gastric acid and pepsin secretion, and enhances mucosal resistance to injury. It is an effective anti-ulcer agent and also has oxytocic properties. Apo-Misoprostol,Cytotec,Glefos,Misoprostol, (11alpha,13E)-Isomer,Misoprostol, (11alpha,13E,16R)-Isomer,Misoprostol, (11alpha,13Z)-(+-)-Isomer,Misoprostol, (11alpha.13E,16S)-Isomer,Misoprostol, (11beta,13E)-(+-)-Isomer,Misoprostol, (11beta,13E,16R)-Isomer,Misoprostol, (11beta,13E,16S)-Isomer,Novo-Misoprostol,SC-29333,SC-30249,Apo Misoprostol,Novo Misoprostol,SC 29333,SC 30249,SC29333,SC30249

Related Publications

T Kutlu, and S Tuğrul, and T Aran, and H Uslu, and S Eren, and O Oral
Misoprostol to treat missed abortion in the first trimester.
December 2007, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
T Kutlu, and S Tuğrul, and T Aran, and H Uslu, and S Eren, and O Oral
Intravaginal misoprostol for medical evacuation of first trimester missed abortion.
July 1998, Primary care update for Ob/Gyns,
T Kutlu, and S Tuğrul, and T Aran, and H Uslu, and S Eren, and O Oral
Experience with misoprostol in the management of missed abortion in the second trimester.
August 2005, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology,
T Kutlu, and S Tuğrul, and T Aran, and H Uslu, and S Eren, and O Oral
Use of misoprostol in first and second trimester abortion: a review.
September 1999, Obstetrical & gynecological survey,
T Kutlu, and S Tuğrul, and T Aran, and H Uslu, and S Eren, and O Oral
Second trimester abortion using intravaginal misoprostol.
February 1998, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
T Kutlu, and S Tuğrul, and T Aran, and H Uslu, and S Eren, and O Oral
Second trimester abortion using intravaginal misoprostol.
June 2005, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
T Kutlu, and S Tuğrul, and T Aran, and H Uslu, and S Eren, and O Oral
Sublingual misoprostol for second-trimester abortion.
January 2004, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
T Kutlu, and S Tuğrul, and T Aran, and H Uslu, and S Eren, and O Oral
Comparative study of intravaginal misoprostol with gemeprost as an abortifacient in second trimester missed abortion.
August 1997, The Australian & New Zealand journal of obstetrics & gynaecology,
T Kutlu, and S Tuğrul, and T Aran, and H Uslu, and S Eren, and O Oral
Vaginal misoprostol before first trimester abortion.
February 1998, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,
T Kutlu, and S Tuğrul, and T Aran, and H Uslu, and S Eren, and O Oral
Vaginal misoprostol for early second-trimester abortion.
June 1998, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception,
Copied contents to your clipboard!